Learn more about the #1 prescribed FDA-approved anti-vascular endothelial growth factor treatment for patients with Macular Edema following Retinal Vein Occlusion (MEfRVO).1
Hey there! I'm Lea, and I'm your digital guide here to help you navigate around the EYLEA® (aflibercept) Injection website. I can help you search for information, find resources and answer your questions.
Type something below to get started!
EYLEA has been studied in more than 3,000 people with certain diseases of the retina .
EYLEA is a prescription medication given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
EYLEA is an anti– vascular (anti-VEGF) treatment that is given by injection into the eye and works to block VEGF by trapping it between its molecular arms. endothelial growth factor
VEGF is a protein made by the blood vessels that, at high levels, can cause blood vessels to leak fluid and also result in the growth of abnormal blood vessels.2 Symptoms of MEfRVO happen as the macula swells with fluid.3,4 Blocking VEGF helps reduce the fluid leaking into the macula .2
If you and your eye doctor decide that EYLEA is right for you, we have multiple support options that may be able to help. Whether you have government insurance (like Medicare), private health insurance, or no coverage for EYLEA, we are here to help.
In two clinical studies, 358 people with MEfCRVO received injections of EYLEA (2 mg) either once every 4 weeks or control
Both studies measured the percentage of people whose vision was maintained (not losing 15 or more letters, or 3 lines, on the eye chart. ) at 6 months compared to the number of letters they saw when each study started.
In a clinical study, 181 people with MEfBRVO received
injections of EYLEA (2 mg) either once every 4 weeks
The study measured the percentage of people gaining at least 15 letters (3 lines) on the eye chart at 6 months compared to the number of letters they saw when the study started.
At 6 months, (3 lines)on the eye chart. 89% to 94% of people treated with EYLEA were able to see the same number of letters or more letters on the eye chart.1treated with EYLEA gained at least 15 letters
At 6 months, (3 lines)on the eye chart. 98% of people treated with EYLEA were able to see the same number of letters or more letters on the eye chart.5treated with EYLEA gained at least 15 letters
At 6 months, people treated with EYLEA saw, on average,
than when each study started.
than when the study started.
The number of letters gained by people treated with EYLEA was much greater than control.
These results are from 2 clinical studies; your individual results may vary. Discuss with your eye care team if EYLEA is right for you.
These results are from a clinical study; your individual results may vary. Discuss with your eye care team if EYLEA is right for you.
The recommended dose of EYLEA for MEfRVO is 2 mg administered by injection in the eye monthly (every 4 weeks).
Your eye care team will want to see you regularly to check your vision and also check your treatment progress with EYLEA. Work with your eye care team to make sure you can keep your appointments and stay on your recommended treatment schedule.
EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
As with all therapeutic proteins, there is a potential for an immune response in patients treated with EYLEA.
It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.